Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma.
about
Specificity delivers: therapeutic role of tumor antigen-specific antibodies in pancreatic cancerThe pancreas cancer microenvironmentPancreatic cancer: New hopes after first line treatmentProgression-free Survival Decreases with Each Subsequent Therapy in Patients Presenting for Phase I Clinical Trials.Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from a phase 3 trial (MPACT).BIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer.Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials.Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers.Monoclonal antibodies in the treatment of pancreatic cancer.Beyond first-line chemotherapy for advanced pancreatic cancer: an expanding array of therapeutic options?Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer models.Recent advances for the treatment of pancreatic and biliary tract cancer after first-line treatment failure.Overview of pre-clinical and clinical studies targeting angiogenesis in pancreatic ductal adenocarcinoma.Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3-MYC Interactions as a Target in Pancreatic Cancer.Current status and dilemma of second-line treatment in advanced pancreatic cancer: is there a silver lining?
P2860
Q26853171-6A21BC8C-8B0F-4EF0-825C-73D583893213Q27026705-3BCCF645-E605-4882-B5A2-3FB1A62C5AC2Q28067055-2AE2E556-ADD5-443D-84D8-FE3B53CA45DFQ35632548-8E2220C3-FA0C-4B26-8CC3-994C52F80A5BQ36171310-BC5C0233-1550-475A-A6E2-A66BA72A7956Q36927086-D0F5E8C3-A76F-4284-B704-54DD8E0BB364Q37032865-91D7E0D7-0076-4E81-92FC-B514F79BB37DQ37354443-01E5EA92-DDB1-4C68-8489-B1828D586622Q37355568-7B472ED7-5604-4BA1-8EBF-26CD2193B2EDQ37617955-18169F61-68B1-4139-A102-898C0851BD76Q37706198-67C79563-475D-4F6B-AC7E-B4FB484FC092Q38577917-F905FDB5-C8B0-4A33-8466-9DB1C9C5E3E7Q38684978-41E8866A-E0EC-4252-B849-07A4D042CE13Q50304177-F248EE88-F0E9-4410-A863-9B52F0C8BCBBQ58799265-90C7FD1B-24BA-4F8D-8B65-C84F6954A6BB
P2860
Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Phase II and coagulation casca ...... tic pancreatic adenocarcinoma.
@ast
Phase II and coagulation casca ...... tic pancreatic adenocarcinoma.
@en
Phase II and coagulation casca ...... tic pancreatic adenocarcinoma.
@nl
type
label
Phase II and coagulation casca ...... tic pancreatic adenocarcinoma.
@ast
Phase II and coagulation casca ...... tic pancreatic adenocarcinoma.
@en
Phase II and coagulation casca ...... tic pancreatic adenocarcinoma.
@nl
prefLabel
Phase II and coagulation casca ...... tic pancreatic adenocarcinoma.
@ast
Phase II and coagulation casca ...... tic pancreatic adenocarcinoma.
@en
Phase II and coagulation casca ...... tic pancreatic adenocarcinoma.
@nl
P2093
P2860
P921
P1476
Phase II and coagulation casca ...... tic pancreatic adenocarcinoma.
@en
P2093
André Rogatko
Barbara A Burtness
Igor A Astsaturov
James C Watson
Jonathan D Cheng
Louis M Weiner
Neal J Meropol
R Katherine Alpaugh
Steven J Cohen
Sue McLaughlin
P2860
P356
10.1097/COC.0B013E3181D2734A
P577
2011-02-01T00:00:00Z